Evercore ISI Group Maintains In-Line on Editas Medicine, Lowers Price Target to $7
Portfolio Pulse from Benzinga Newsdesk
Evercore ISI Group analyst Liisa Bayko maintains an In-Line rating on Editas Medicine (NASDAQ:EDIT) but lowers the price target from $15 to $7.
May 30, 2024 | 3:14 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Evercore ISI Group has maintained an In-Line rating on Editas Medicine but significantly lowered the price target from $15 to $7.
The significant reduction in the price target from $15 to $7 by Evercore ISI Group suggests a negative outlook on Editas Medicine's future performance. This is likely to result in a short-term decline in the stock price as investors react to the lowered expectations.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100